What Blood Types Should Not Have Babies Together?

No blood type combination makes it unsafe or inadvisable for a couple to have children, but certain mismatches between a mother’s blood type and her baby’s can trigger an immune reaction that harms the baby’s red blood cells. The most well-known mismatch is Rh incompatibility, where an Rh-negative mother carries an Rh-positive baby, but ABO mismatches and rarer antigen differences can also cause problems. The good news is that modern medicine has effective tools for prevention, monitoring, and treatment, so the real question is less about which couples “should not” have babies and more about which combinations need extra medical attention.

How a Mother’s Immune System Can Attack Her Baby’s Blood

The underlying issue in all blood type incompatibilities during pregnancy is the same: the mother’s immune system recognizes something on the baby’s red blood cells as foreign and produces antibodies against it. These antibodies, specifically a type called IgG, are small enough to cross the placenta and enter the baby’s bloodstream. Once there, they latch onto the baby’s red blood cells and mark them for destruction. This process is called hemolytic disease of the fetus and newborn, or HDFN.¹

When a baby’s red blood cells are destroyed faster than the body can replace them, the consequences range from mild jaundice to severe anemia, fluid buildup (called hydrops fetalis), brain damage, or even stillbirth. The severity depends on which blood group system is involved, how many antibodies the mother produces, and how early the immune response kicks in. This is why some mismatches are far more dangerous than others.

Rh Incompatibility Is the Most Dangerous Mismatch

When people talk about blood types that “shouldn’t have babies together,” they are almost always thinking of the Rh factor. If a mother is Rh-negative and the father is Rh-positive, there is a good chance the baby will be Rh-positive too. The mother’s immune system can then become sensitized to the Rh D antigen on the baby’s red blood cells, particularly if fetal blood leaks into her circulation during delivery, miscarriage, or certain procedures like amniocentesis.²

A first pregnancy is usually not a problem. The mother’s body needs time to build up antibodies, and by the time it does, the first baby has often already been born. The real danger comes in subsequent pregnancies. If the mother has been sensitized, her immune system already has a stockpile of anti-D antibodies ready to attack the next Rh-positive baby. That second or third baby can face severe anemia while still in the womb. Several factors increase the risk of this sensitization, including the volume of fetal blood that mixes with the mother’s, her genetic makeup, and any previous blood transfusions she may have received.³

How common is Rh negativity? It varies dramatically by population. In people of European descent, roughly 15% are Rh-negative. In parts of sub-Saharan Africa and East Asia, the rate can be below 1%. A study from southern Ethiopia found an Rh-negative prevalence of about 6% among women who delivered at one hospital.⁴ The risk of HDFN from Rh incompatibility exists wherever Rh-negative women live alongside Rh-positive partners, which is essentially everywhere, though the probability differs by region.

ABO Incompatibility Is Common but Usually Milder

ABO blood type mismatches between mother and baby are actually more common than Rh mismatches, yet they tend to cause far less severe disease. The classic scenario involves a mother with type O blood carrying a baby with type A or type B blood. Type O individuals naturally produce anti-A and anti-B antibodies, and some of these are the IgG variety that can cross the placenta.⁵

Unlike Rh disease, ABO incompatibility can affect a first pregnancy because the mother already has anti-A or anti-B antibodies before she ever becomes pregnant. But the flip side is that ABO disease is almost always mild. Most babies with ABO incompatibility develop nothing worse than moderate jaundice in the first few days of life, which responds well to phototherapy. Severe anemia requiring invasive treatment is unusual. Newborns with this mismatch are at greater risk for significant jaundice, so monitoring bilirubin levels in the first few days matters.⁶

A large retrospective study looking at exchange transfusions for severe jaundice in newborns found that ABO incompatibility accounted for about 38% of cases, split roughly between type A babies of type O mothers (26%) and type B babies of type O mothers (12%). Rh D incompatibility made up another 38%.⁷ So while ABO disease is usually mild, it is not always trivial, and in a small number of cases it leads to the same kind of dangerous bilirubin buildup as Rh disease.

Kell and Other Minor Blood Group Antigens

Most people have never heard of the Kell blood group system, but obstetricians pay close attention to it. After the Rh D antigen, the Kell antigen (specifically K, or KEL1) is the most potent trigger of immune-mediated fetal anemia. Kell-related HDFN occurs in roughly 0.1 to 0.3% of pregnancies but accounts for about 10% of cases of severe fetal anemia caused by antibodies.⁸

What makes Kell especially treacherous is the mechanism. With Rh disease, the mother’s antibodies destroy the baby’s circulating red blood cells, causing anemia through hemolysis. With Kell, the antibodies also suppress the baby’s ability to make new red blood cells in the bone marrow. This means that standard monitoring tools, which look for signs of red blood cell breakdown, can underestimate how anemic the baby really is. One reported case of anti-K antibodies led to intrauterine fetal death at 32 weeks with hydrops fetalis.⁹

Kell sensitization is most commonly caused by prior blood transfusions rather than by previous pregnancies. A woman who received Kell-positive blood at some point may develop anti-K antibodies that then threaten a future Kell-positive baby. This is one reason why blood banks try to match Kell-negative blood for women of childbearing age whenever possible. Other minor blood group systems, including Duffy, Kidd, and MNS, can occasionally cause HDFN too, though they do so far less often. Current preventive measures like anti-D immunoglobulin target only the Rh D antigen, leaving no equivalent prophylaxis for Kell or these other systems.³

How Anti-D Immunoglobulin Prevents Rh Disease

The single biggest advance against blood type incompatibility in pregnancy came in the 1960s with the development of anti-D immunoglobulin, commonly known by brand names like RhoGAM. The idea is elegantly simple: if you inject anti-D antibodies into an Rh-negative mother shortly after she is exposed to Rh-positive fetal blood, those antibodies destroy the fetal red blood cells before her own immune system has a chance to recognize them and mount a lasting response. She never becomes sensitized, and future pregnancies remain safe.

In practice, Rh-negative pregnant women receive a dose of anti-D immunoglobulin around 28 weeks of pregnancy and again within 72 hours of delivering an Rh-positive baby. Additional doses are given after events that could cause fetal blood to enter the mother’s circulation, such as miscarriage, ectopic pregnancy, amniocentesis, or abdominal trauma.

The results have been dramatic where the treatment is used consistently, but globally the picture is mixed. International guidelines from FIGO and ICM note that anti-D immunoglobulin has only reduced Rh disease by about 50% worldwide, largely because access and uptake remain low in many countries.¹⁰ A systematic review of the evidence found that fewer women who received anti-D at delivery became sensitized compared to those who did not, though the certainty of evidence was rated low.¹¹ Even so, in countries with robust prenatal care, Rh disease has gone from being a leading cause of infant death to a relatively rare complication. The problem is not that the treatment does not work; it is that too many women around the world still do not get it.

Modern Monitoring and Diagnosis

One of the frustrations with blood type incompatibility used to be that doctors could not easily know whether a baby was at risk without invasive procedures. If a mother was Rh-negative, you had to assume the baby might be Rh-positive and manage accordingly, or else do an amniocentesis to find out, which itself carries a small risk of triggering more fetal-maternal blood mixing.

Cell-free DNA testing has changed this. During pregnancy, fragments of fetal DNA circulate in the mother’s blood. Laboratories can now isolate these fragments and determine the baby’s Rh status from a simple maternal blood draw. Studies have confirmed that this approach accurately predicts whether the fetus is Rh-positive in all three trimesters.¹² A more recent U.S.-based evaluation specifically assessed the clinical performance of a next-generation sequencing-based assay for fetal RhD detection in a diverse population of Rh-negative pregnant individuals.¹³

This matters practically because if a cell-free DNA test shows the baby is Rh-negative (like the mother), there is no mismatch and no need for anti-D immunoglobulin. The mother avoids unnecessary injections, and healthcare resources are better directed. In several European countries, this kind of targeted approach is already standard practice.

For pregnancies already complicated by antibodies, doctors monitor the baby using ultrasound to measure blood flow in a brain artery called the middle cerebral artery. When a fetus is becoming anemic, blood flows faster through this vessel because the blood is thinner. This noninvasive measurement has largely replaced amniocentesis for tracking the severity of fetal anemia.

Paternal testing can also help clarify risk. If the father is known to be heterozygous for the RhD gene, meaning he carries one copy, the baby has only a 50% chance of being Rh-positive. Molecular methods can determine the father’s RhD zygosity with high accuracy, which helps guide how aggressively doctors need to monitor a given pregnancy.¹⁴

What Happens When Prevention Fails

When a fetus develops severe anemia despite preventive efforts, the primary rescue treatment is intrauterine blood transfusion. A specialist uses ultrasound guidance to insert a needle through the mother’s abdomen into the umbilical vein and infuses carefully prepared donor red blood cells directly into the fetal bloodstream. The procedure has been performed since 1963 and remains the standard treatment for severe fetal anemia.¹⁵

Intrauterine transfusion sounds alarming, and it does carry risks, but in experienced hands the outcomes are remarkably good. A series from a Belgian center covering 135 intrauterine transfusions for alloimmune anemia reported zero fetal, peripartum, or neonatal deaths. Mild complications such as prolonged bleeding at the needle site or uterine contractions occurred in about one in ten procedures, and severe complications occurred in only two out of 135.¹⁶ Some babies need multiple transfusions before they are mature enough to be delivered safely.

After birth, babies affected by HDFN may need phototherapy for jaundice, intravenous immunoglobulin, or in severe cases an exchange transfusion, where a large volume of the baby’s blood is gradually removed and replaced with compatible donor blood. Phototherapy should begin immediately after birth in at-risk newborns, and cord blood testing for blood group, direct antiglobulin test, packed cell volume, and bilirubin helps guide early decisions.¹⁷ The overall trend is encouraging: exchange transfusions have become less common over time as prevention and earlier interventions have improved.

Rare Blood Phenotypes That Raise the Stakes

Beyond the familiar ABO and Rh systems, some extremely rare blood types create unique risks that even experienced clinicians rarely encounter. The Bombay phenotype is a good example. People with this phenotype lack the H antigen that serves as the foundation for A and B antigens on red blood cells. Their blood tests as type O, but it is functionally different from ordinary type O. Mothers with the Bombay phenotype produce anti-H antibodies that can cross the placenta and attack a baby’s red blood cells. A case report documented clinically significant hemolysis in a newborn with a Bombay-phenotype mother, and because these antibodies are preformed rather than developing during pregnancy, even the first baby is at risk.¹⁸

The closely related para-Bombay phenotype presents its own challenges. A case from Malaysia described a para-Bombay mother whose extremely premature baby required transfusion, though it was difficult to distinguish whether the transfusion need was driven by prematurity or by HDFN.¹⁹ These phenotypes are most common in parts of South Asia, though they can appear in any population. When rare phenotypes are involved, finding compatible blood for transfusion becomes an additional logistical headache on top of the immunological problem.

Complications in Donor-Egg and Assisted Reproduction Pregnancies

Assisted reproduction adds a wrinkle that many prospective parents do not anticipate. When a woman conceives using a donor egg, the baby’s blood type may differ from hers in ways that would not be possible with her own eggs. The same applies when a surrogate carries a pregnancy. These scenarios can increase the chance of unfamiliar antigen mismatches.

A case report described a 51-year-old woman who underwent IVF with donor eggs and her husband’s sperm. During the pregnancy she developed antibodies against two different red blood cell antigens, anti-Ce (part of the Rh system) and anti-Jka (part of the Kidd system). The anti-Jka antibodies disappeared in the third trimester only to resurface after delivery, complicating plans for compatible blood transfusion if she needed one.²⁰ This pattern of antibodies appearing and vanishing makes management particularly tricky. Older egg-recipient mothers may also have a longer history of blood transfusion exposure, further raising the risk of having pre-existing antibodies to less common antigens.

The Emotional Burden on Parents

Most discussions of blood type incompatibility focus on the medical details, but the psychological toll on families deserves attention. A closely related condition, fetal-neonatal alloimmune thrombocytopenia (FNAIT), involves a similar immune mechanism but targets the baby’s platelets rather than red blood cells. A study of mothers whose pregnancies were affected by FNAIT found that over half reported psychological problems lasting more than six weeks, including anxiety (90%), stress, depression, and sleep disturbances. The symptoms were worse among mothers whose child did not survive an intracranial hemorrhage and those who had multiple affected pregnancies.²¹

While this study looked at platelet-related disease rather than red blood cell disease, the emotional experience is broadly similar for parents navigating any form of alloimmune pregnancy complication. The unpredictability of severity from one pregnancy to the next, the invasive monitoring, the possibility of intrauterine transfusions, and the fear that a healthy first baby does not guarantee a healthy second one all contribute to sustained anxiety. Parents going through this often feel isolated because the condition is poorly understood by friends and family. If you are in this situation, connecting with support groups or a counselor who understands high-risk pregnancy can make a real difference.

What Couples Should Actually Do

If you are planning a pregnancy or already pregnant, standard prenatal bloodwork will identify your ABO type and Rh status. If you are Rh-negative, your provider will check for anti-D antibodies and recommend anti-D immunoglobulin at the appropriate times. If antibodies to any red blood cell antigen are found during routine screening, additional monitoring of the baby through ultrasound and possibly cell-free DNA testing will follow.

There is no blood type pairing that means you should avoid having children. Rh-negative women safely have babies with Rh-positive partners every day with the help of anti-D prophylaxis. ABO mismatches between type O mothers and non-O babies usually cause nothing worse than a few days under the phototherapy lights. Even Kell sensitization and rarer antigen problems are manageable with expert monitoring and, when necessary, intrauterine transfusion. The key is early detection, which is why prenatal blood typing and antibody screening exist as standard parts of care in the first place. If your blood work turns up something unexpected, a maternal-fetal medicine specialist can walk you through the specific risks and monitoring plan for your pregnancy.